Title
Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: The very large database of Lipids studies 6 and 7
Date Issued
01 January 2019
Access level
open access
Resource Type
journal article
Author(s)
Hendrani A.D.
Baradaran-Noveiry B.
Martin S.S.
Brown E.
Kulkarni K.R.
Banach M.
Toth P.P.
Brinton E.A.
Jones S.R.
Joshi P.H.
Centro Johns Hopkins Ciccarone para la Prevención de las Enfermedades Cardiovasculares
Publisher(s)
Termedia Publishing House Ltd.
Abstract
Introduction: The association between triglycerides (TG) and cardiovascular diseases is complex. The classification of hypertriglyceridemic (HTG) phenotypes proposed by Fredrickson, Levy and Lees (FLL) helps inform treatment strategies. We aimed to describe levels of several lipoprotein variables from individuals with HTG FLL phenotypes from the Very Large Database of Lipids. Material and methods: We included fasting samples from 979,539 individuals from a contemporary large study population of US adults. Lipids were directly measured by density-gradient ultracentrifugation using the Vertical Auto Profile test while TG levels were measured in whole plasma using the Abbott ARCHITECT C-8000 system. Hyperchylomicronemic (Hyper-CM) and non-chylomicronemic (non-CM) phenotypes were defined using computationally derived models. Individuals with FLL type IIa phenotype were excluded. Distributions of lipid variables were compared using medians and Kruskal-Wallis test. Results: A total of 11.9% (n = 116,925) of individuals met criteria for HTG FLL phenotypes. Those with hyper-CM phenotypes (n = 5, < 0.1% of population) had two-fold higher TG levels compared with non-chylomicronemic (non-CM) individuals (11.9% of population) (p < 0.001). Type IIb individuals had the highest non-HDL-C levels (median 242 mg/dl). Cholesterol in large VLDL1+2 particles was higher than in small VLDL3 particles in all phenotypes except FLL type III. Hyper-CM phenotypes had significantly lower HDL-C levels but greater HDL2/HDL3-C ratio compared to non-CM phenotypes. Cholesterol content of the lipoprotein (a) peak was significantly higher in the hyper-CM groups compared to non-CM phenotypes (p < 0.0001). Conclusions: This observational hypothesis-generating study provides insight into the complexity of lipid metabolism in HTG phenotypes, including less traditional lipid measures such as LDL density, HDL subclasses and Lp(a)-C.
Start page
1195
End page
1202
Volume
15
Issue
5
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Scopus EID
2-s2.0-85072178988
Source
Archives of Medical Science
ISSN of the container
1734-1922
Sponsor(s)
Drs. Martin and Jones are listed as coinventors on a pending patent filed by Johns Hopkins University for LDL-C estimation. Dr Jones has served as an advisor to Sano/Regeneron. Dr Martin has served as a consultant to Quest Diagnostics, Sano/Regeneron, Amgen, and the Pew Research Center. Dr. Joshi received non-compensated site PI for studies funded by AstraZeneca, Pfizer, Merck and Regeneron/Sanofi as well as modest consulting income from Regeneron. Dr. Toth has served as consultant and speaker for Amarin, Amgen, Kowa, Merck, Novo-Nordisk, Regeneron, and Sanofi; consultant to Gemphire. Dr. Brinton has received research support from Amarin, Kowa and the National Institutes of Health; honoraria as consultant for Akcea, Alexion, Amarin, Amgen, Janssen, Kastle, Kowa, Merck, Precision Biosciences, PTS Diagnostics, Regeneron, Sanofi-Aventis; honoraria as speaker for Akcea, Alexion, Amarin, Am-gen, Boehringer-Ingelheim, Janssen, Kastle, Kowa, Merck, Novo-Nordisk, Regeneron, Sanofi-Aventis.
Sources of information: Directorio de Producción Científica Scopus